Phase Ib/II Trial of Lurbinectedin Plus Irinotecan in Patients With Advanced Solid Tumors

May 29-31, 2020; Online at meetings.asco.org/am
Combined treatment with lurbinectedin and irinotecan yields promising early antitumor activity in small-cell lung cancer, with an ORR of 69.2% in 13 evaluable patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 232 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Released: May 13, 2022

On-demand webcast on biomarker-driven care for patients with NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Downloadable slides for oncologists, pharmacists, and nurses: Immunotherapy and chemotherapy for extensive-stage SCLC from Clinical Care Options (CCO)

Released: May 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings